Furthermore, EPIC1 has been evidenced to block the presentation of tumor antigens in BC, thereby facilitating the immune escape of tumor cells and contributing to resistance against checkpoint inhibitor therapy in mouse models [56]. Here, EPIC1 is linked to breast cancer.